logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

MRD-positive BCP-ALL: blinatumomab+stem cell transplant yields better RFS

50% reduction in risk for relapse or death with blinatumomab.